This segment focuses on the research, development, and commercialization of sacral neuromodulation (SNM) systems. Axonics' primary product is a rechargeable SNM system (r-SNM) that delivers mild electrical pulses to the sacral nerve to treat overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Research and development efforts are focused on improving the longevity, efficacy, and patient experience of SNM therapy. Technologies include implantable pulse generators, tined leads, and advanced programming capabilities. The patient impact is significant, offering a minimally invasive solution to improve bladder and bowel control, leading to a better quality of life. Axonics holds a strong market position with its rechargeable system, competing with Medtronic. Future opportunities include expanding into new geographic markets and developing next-generation SNM devices. Regulatory and clinical aspects involve FDA approvals and ongoing clinical trials to demonstrate safety and efficacy. Partnerships may include collaborations with urology clinics and hospitals.

This segment involves the commercialization of Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence (SUI). Bulkamid is a minimally invasive treatment option that involves injecting the bulking agent into the urethra to improve bladder control. Research and development efforts focus on optimizing the delivery and long-term effectiveness of Bulkamid. The technology involves the use of a biocompatible hydrogel material. The therapeutic area is women's health, specifically addressing SUI, which affects millions of women worldwide. The patient impact is improved continence and quality of life. Axonics' market positioning is in the women's health segment, offering an alternative to more invasive surgical procedures. Future opportunities include expanding the use of Bulkamid in new markets and exploring potential applications in other urological conditions. Regulatory and clinical aspects involve FDA approvals and post-market surveillance. Partnerships may include collaborations with gynecologists and urologists.